Estimating the extent of myocardial damage in patients with STEMI using the DETERMINE score

Christina Tiller,1 Magdalena Holzknecht,1 Martin Reindl,1 Ivan Lechner,1 Verena Kalles,1 Felix Trojan,2 Johannes Schwaiger,3 Agnes Mayr,2 Gert Klug,1 Christoph Brenner,1 Axel Bauer,1 Bernhard Metzler,1 Sebastian Johannes Reinstadler2

ABSTRACT

Background Recently, a simple ECG score (DETERMINE score) has been proposed for estimating myocardial scar in patients with ischaemic cardiomyopathy. We sought to evaluate the usefulness of the DETERMINE score for the assessment of myocardial infarct size (IS) as well as microvascular obstruction (MVO), in the setting of ST-elevation myocardial infarction (STEMI).

Methods This observational study enrolled 423 patients with STEMI (median age 56, 17% women), revascularised by primary percutaneous coronary intervention (PCI). For evaluation of the DETERMINE and Selvester scoring system (an established but complex ECG score for IS estimation), ECG was conducted before discharge (median: 4 IQR 2–6 days). Cardiac magnetic resonance (CMR) was conducted within a week after infarction for determination of IS and MVO.

Results Median DETERMINE score of the overall cohort was 8 points (IQR 5–11). A higher DETERMINE score was significantly associated with a larger IS (21% vs 11% of left ventricular myocardial mass (LVMM), p<0.001) as well as larger MVO (1.2% vs 0.0% of LVMM, p<0.001). In linear and binary multivariable logistic regression analysis, the DETERMINE score remained independently associated with IS (OR 1.09, 95% CI 1.02 to 1.17, p=0.014) and MVO (OR 1.12, 95% CI 1.04 to 1.21, p=0.003), after adjustment for Selvester score and clinical indicators of IS (high-sensitivity cardiac troponin T, high-sensitivity C reactive protein, N-terminal pro-B-type natriuretic peptide, TIMI flow pre-interventional and post-interventional PCI, anterior infarct localisation).

Conclusions In patients undergoing PCI for STEMI, the DETERMINE score provides an easy and inexpensive tool for appropriate estimation of infarct severity as determined by CMR.

INTRODUCTION

The degree of myocardial tissue injury in the setting of ST-elevation myocardial infarction (STEMI) represents a main determinant of clinical outcome.1

Cardiac magnetic resonance (CMR) is the gold standard modality for non-invasive infarct severity characterisation after STEMI.2

Key questions

What is already known about this subject?

► The ECG represents the first-line diagnostic tool in patients with suspected ST-elevation myocardial infarction (STEMI). Recently, a simple ECG score (DETERMINE score), which combines Q waves, fragmented ORS and inverted T waves, has been proposed for the assessment of myocardial scar after myocardial infarction. However, the usefulness of the DETERMINE score for the estimation of myocardial and microvascular injury in patients with STEMI is unknown.

What does this study add?

► The present study illustrates that the DETERMINE score is independently associated with infarct size and microvascular obstruction, determined by comprehensive cardiac MRI, in survivors of STEMI.

How might this impact on clinical practice?

► The DETERMINE score might provide as an easy and rapidly available tool for estimating the extent of myocardial as well as microvascular injury in patients with STEMI and might be used for risk stratification in the early phase after myocardial infarction.

It allows a comprehensive view on the myocardium tissue level including the detection and quantification of infarct size (IS) and microvascular obstruction (MVO).3 Both parameters have been proven to be of major prognostic relevance in patients with revascularised STEMI. However, in clinical practice, CMR imaging is hampered by restricted availability.

The ECG represents the first-line diagnostic tool in patients with suspected myocardial infarction and might be also useful for the estimation of myocardial infarct severity. Its universal availability and low costs in daily routine is a major advantage. In recent years, several ECG markers have been proposed as potential useful indicators of the extent
of myocardial damage including Q-waves, fragmented QRS and T-wave inversions. More recently, a simple ECG score (DETERMINE score) which combines Q waves, fragmented QRS and inverted T waves has been proposed as a promising tool for the assessment of myocardial scar in patients with a history of MI. However, the usefulness of the DETERMINE score for the estimation of myocardial and microvascular injury in the acute phase after MI is unknown. The purpose of the present study was, therefore, to assess the value of a simple ECG score, named the DETERMINE score, for the evaluation of myocardial as well as microvascular injury, as assessed by CMR imaging, in a well-defined cohort of patients with STEMI revascularised by primary percutaneous coronary intervention (PCI).

METHODS

Study design and clinical measurements

This observational study included 423 consecutive patients with STEMI who were prospectively enrolled in the MAGnetic Resonance IN Acute STEMI (MARINA-STEMI) trial (NCT04113356). Diagnosis of STEMI was in accordance with the ESC/ACC committee criteria, and all patients were revascularised by primary PCI within 24 hours after symptom onset. For inclusion, first STEMI patients with no history of earlier MI or coronary intervention was required as well as an estimated glomerular filtration rate >30 mL/min/1.73 m² and Killip class <III at time of CMR scan. Exclusion criteria were age below 18 years and contraindications for CMR (pacemaker, aneurysm clips, orbital foreign body, claustrophobia, known or suggested contrast agent allergy to gadolinium).

Measurements of high-sensitivity cardiac troponin T (hs-cTnT) were determined by using an enzyme immunoassay (hs-cTnT, E170; Roche Diagnostics, Vienna, Austria) according to the standard protocols of our working group as described previously. For measurements of high-sensitivity C reactive protein (hs-CRP), the c702 module of cobas 8000 (Roche Diagnostics) was applied. N-Terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measured by a commercially available assay (E170 instrument proBNP II assay; Roche Diagnostics).

A detailed medical history including current medications and presence of cardiovascular risk factors were assessed during hospitalisation. All patients gave written informed consent prior to study inclusion.

Patient and public involvement statement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Electrocardiography

For electrocardiographic analyses, a standard 12-lead surface ECG (voltage: 10 mm/mV; speed: 25 mm/s) was conducted before discharge, at a median of 4 (IQR 2–6) days after the index event. DETERMINE and Selvester score (37 criteria/29 points) were evaluated manually by two experienced investigators, blinded to CMR data. DETERMINE score was defined as follows: (number of leads with Q waves (x2))+(number of leads with fragmented QRS)+(number of leads with inverted T waves).

Pathological Q waves were defined as any Q wave with duration >40 ms and Q/R wave amplitude ratio >0.25 mV or absence of an R wave. Fragmented QRS was defined by QRS duration <120 ms and the RSR' pattern, specified by the presence of an additional R wave (R') or notchings in the nadir of the S wave, or the presence of >1 R' (fragmentation). T-Wave inversion was defined as the presence of an inverted T wave in at least one of the infarct-related leads with the nadir deeper than 0.1 mV. Lead aVR (augmented Vector Right) was excluded from all ECG analyses. In addition, patients with bundle branch or fascicular block and true posterior infarction were excluded (n=18).

Cardiac MRI

All scans were performed on a 1.5 T MRI unit (AVANTO-scanner; Siemens, Healthineers AG, Erlangen, Germany) at a median of 3 (IQR 2–5) days after infarction. A detailed imaging and post-processing protocol of our working group was published in detail previously. Left ventricular (LV) morphology and function were conducted on short-axis cine images using retrospective ECG-triggered true-FISP bright-blood sequences acquired using breath hold. Standard software (ARGUS; Siemens, Healthineers AG) was used for post-processing analyses. Papillary muscles were excluded from myocardial mass and included in the LV volume. For LV strain analyses, a tissue tracking software was used (Circle Cardiovascular Imaging, Calgary, Canada); short-axis and long-axis images were available for 390 patients. Late gadolinium enhancement (LGE) images were acquired 15 min after the application of a 0.2 mmol/kg bolus of contrast agent (Gadovist; Bayer Vital, Leverkusen, Germany), using an ECG-triggered phase-sensitive inversion recovery sequence with consecutive short-axis slices. The extent of LGE was determined quantitatively on each slice using IMPAX EE workstation (Agfa HealthCare, Bonn, Germany) by defining ‘hyperenhancement’ at a threshold of ±5 SD above the signal intensity of remote myocardium in the opposite myocardial segment of the LV.

MVO were expressed as percentages of LV myocardial mass (LVMM). Image analyses were performed by an established CMR core laboratory blinded to clinical and ECG data.

Statistical analysis

Continuous variables were expressed as median with corresponding IQR. Categorical variables were presented as frequencies with corresponding percentages. Differences in continuous variables were compared by the Mann-Whitney U test and differences in categorical variables were tested by the χ² test. Kruskal-Wallis test
was used to test differences in more than two groups. Patients were dichotomised by the median DETERMINE score (8 points). Receiver operating characteristic curve analysis was applied to evaluate the area under the curve (AUC) for the prediction of large IS (IS >19%) and large MVO (MVO >1.4%). AUC values were compared according to a method characterised by DeLong et al.15

Linear and binary multivariable regression analyses were performed to assess the value of the DETERMINE score for the prediction of IS as well as MVO. For binary logistic regression analysis, IS and MVO were dichotomised by prognosis-based cut-off values (IS >19%, MVO >1.4%).16

For the assessment of the coefficients of variability of the DETERMINE score, the SD of differences between the calculations was divided by the mean value of these assessments. For all analyses, two-tailed p values of <0.05 were considered to indicate statistical significance. Statistical analyses were operated with IBM SPSS Statistics V.25.0 and MedCalc V.19.0 (Ostend, Belgium).

RESULTS

Baseline characteristics

Median age of the study cohort was 56 (IQR 50–66) years and 71 patients (17%) were female. Table 1 summarises the baseline characteristics of the entire study population and according to the median DETERMINE score.

Clinical associates of the determine score

Patients with a median DETERMINE score ≥8 points had more often anterior infarct localisation (64% vs 29%, p<0.001). Regarding biomarkers, patients with a

| Table 1 | Patient characteristics |
|---------|-------------------------|
|         | Total population (n=423) | DETERMINE score <8 (n=207) | DETERMINE score ≥8 (n=216) | P value |
| Age, years | 56 (50–66) | 56 (49–65) | 57 (51–66) | 0.159 |
| Female, n (%) | 71 (17) | 42 (20) | 29 (13) | 0.059 |
| Body mass index, kg/m² | 26 (25–29) | 26 (25–29) | 26 (24–29) | 0.401 |
| Hypertension, n (%) | 212 (50) | 98 (47) | 114 (53) | 0.264 |
| Hyperlipidaemia, n (%) | 239 (57) | 121 (59) | 118 (55) | 0.428 |
| Diabetes mellitus, n (%) | 41 (10) | 20 (11) | 22 (10) | 0.727 |
| Current smoker, n (%) | 233 (55) | 122 (59) | 111 (51) | 0.119 |
| Family history, n (%) | 144 (34) | 76 (37) | 68 (32) | 0.298 |
| Anterior infarct localisation, n (%) | 198 (47) | 60 (29) | 138 (64) | <0.001 |
| TIMI flow 0 pre-pPCI, n (%) | 264 (62) | 121 (59) | 143 (66) | 0.100 |
| TIMI flow 3 post-pPCI, n (%) | 376 (89) | 190 (92) | 186 (86) | 0.063 |
| Total ischaemia time, min | 186 (120–307) | 179 (108–285) | 195 (126–340) | 0.124 |
| Peak hs-cTnT, ng/L | 4890 (2190–8574) | 3117 (1320–5183) | 6957 (4388–10 900) | <0.001 |
| Peak hs-CRP, mg/L | 23 (12–46) | 20 (9–33) | 28 (15–57) | <0.001 |
| Peak NT-proBNP, ng/L | 1165 (560–2152) | 779 (424–1523) | 1553 (758–3044) | <0.001 |
| DETERMINE score | 8 (5–11) | 5 (2–6) | 11 (9–13) | <0.001 |
| Selvester score | 3 (2–5) | 7 (5–9) | <0.001 |
| CMR parameters |
| LVEDV, mL | 148 (125–170) | 144 (121–163) | 154 (128–178) | 0.003 |
| LVESV, mL | 69 (54–86) | 61 (49–80) | 75 (58–96) | <0.001 |
| LVEF, % | 53 (45–59) | 55 (49–61) | 50 (42–56) | <0.001 |
| LV global longitudinal strain, % | −12.0 (−14.1 to −9.7) | −13.4 (−15.4 to −11.3) | −10.8 (−12.8 to −8.8) | <0.001 |
| LV global radial strain, % | 26.3 (20.3–31.9) | 27.3 (21.9–33.2) | 25.6 (19.4–30.8) | 0.005 |
| LV global circumferential strain, % | −14.2 (−16.0 to −11.8) | −15.0 (−16.7 to −12.9) | −13.0 (−14.9 to −10.9) | <0.001 |
| IS, % of LVMM | 16 (8–24) | 11 (4–17) | 21 (14–28) | <0.001 |
| MVO presence | 230 (54) | 79 (38) | 151 (70) | <0.001 |
| MVO extent, % of LVMM | 0.4 (0.0–1.9) | 0.0 (0.0–0.9) | 1.2 (0.0–3.6) | <0.001 |

CMR, cardiac magnetic resonance imaging; hs-CRP, high-sensitivity C reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IS, infarct size; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVMM, left ventricular myocardial mass; MVO, microvascular obstruction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; pPCI, primary percutaneous coronary intervention.
DETERMINE scores ≥8 points showed higher peak levels of hs-cTnT (6957 ng/L vs 3117 ng/L, p<0.001), hs-CRP (28 mg/L vs 20 mg/L, p<0.001) and of NT-proBNP (1553 ng/L vs 779 ng/L, p<0.001) during index hospitalisation. Higher DETERMINE scores were significantly related to higher Selvester score points (7 points vs 3 points, p<0.001). Regarding CMR parameters, patients with a DETERMINE score ≥8 points had a significantly lower LV ejection fraction (50% vs 55%, p<0.001), and worse LV global longitudinal (−10.8% vs −13.4%, p<0.001), radial (25.6% vs 27.3%, p=0.005) and circumferential (−13.0% vs −15.0%, p<0.001) strain. A higher DETERMINE score was significantly associated with a larger IS (21% vs 11% of LVMM, p<0.001). MVO was more frequent (70% vs 38%, p<0.001) as well as more extensive (1.2% vs 0.0% of LVMM, p<0.001) in patients with a DETERMINE score ≥8 points.

Interobserver agreement was high for the DETERMINE score (r=0.957, p<0.001) and corresponding coefficient of variability was 22%.

Utility of the scores for the assessment of myocardial injury

Higher DETERMINE score points were related with a significant and stepwise increase in IS (p<0.001): 0–5 points, 7% (IQR 3%–14%); 6–9 points, 16% (IQR 8%–24%); and ≥9 points, 22% (IQR 16%–28%), respectively (figure 1). AUC values of the DETERMINE score were both higher for the prediction of large IS (AUC=0.76, 95% CI 0.72 to 0.81 vs AUC=0.71, 95% CI 0.66 to 0.76, p=0.050) as well as for the prediction of large MVO (AUC=0.74, 95% CI 0.69 to 0.79 vs AUC=0.69, 95% CI 0.63 to 0.74, p=0.049) as compared with the Selvester score.

When comparing DETERMINE score and pathological Q waves, the AUC for the prediction of large IS was significantly higher for the DETERMINE score than for pathological Q waves (AUC=0.76, 95% CI 0.72 to 0.81, p<0.001 vs AUC=0.63, 95% CI 0.58 to 0.68, p<0.001, AUC difference=p<0.001). Also for the prediction of MVO, the DETERMINE score yielded a significantly higher AUC than pathological Q waves (AUC=0.74, 95% CI 0.69 to 0.79, p<0.001 vs AUC=0.58, 95% CI 0.52 to 0.64, p=0.009, AUC difference=p<0.001).

In linear regression analysis, the DETERMINE score independently predicted large IS (β=0.223, p<0.001) and large MVO (β=0.139, p=0.008) (table 2). Also in area under the ROC curve analysis, the DETERMINE score emerged as independent predictor of large IS (>19% of LVMM) (OR 1.09, 95% CI 1.02 to 1.17, p=0.014) and large MVO (OR 1.12, 95% CI 1.04 to 1.21, p=0.003) after adjustment for Selvester score, hs-cTnT, hs-CRP, NT-proBNP, TIMI flow pre-interventional, and post-interventional PCI and anterior infarct localisation (table 3).

**Figure 1** Relationship between the DETERMINE score (x-axis) and prediction of infarct size (%). IS, infarct size; LVMM, left ventricular myocardial mass.

**DISCUSSION**

In the present study, we evaluated the utility of the DETERMINE score, a combination of Q waves, fragmented QRS and inverted T waves, for estimating IS and MVO in a large and well-defined cohort of patients with STEMI. We could demonstrate a significant positive correlation between the DETERMINE score and IS. Furthermore, the DETERMINE score remained independently associated with IS even after adjustment for other parameters such as Selvester score, a complex ECG score that has been proposed previously for IS estimation, as well as established clinical parameters such as hs-cTnT, hs-CRP, NT-proBNP, TIMI flow pre-interventional, and post-interventional PCI and anterior infarct localisation. Moreover, we observed a significant and independent association of the DETERMINE score with MVO, a severe marker of reperfusion injury with major prognostic implications in patients with STEMI.

Together, these data suggest a close relation between the DETERMINE score and myocardial as well as microvascular injury as determined by CMR imaging in patients with STEMI. Therefore, this ECG score provides an easy and rapid available tool for early infarct severity assessment post-STEMI.

**ECG markers and infarct size**

The magnitude of myocardial injury represents a major determinant for the prognosis after STEMI. CMR imaging enables a precise and comprehensive infarct characterisation; however, it is still hampered by restricted availability and high costs. ECG offers an inexpensive and universally available tool for estimating myocardial injury after STEMI. Several promising ECG markers have been proposed for the assessment of IS. In particular, the role of pathological Q waves has been studied extensively resulting in good correlation with myocardial tissue injury. Also, the presence of fragmented QRS was demonstrated with larger areas of ischaemic injury. Moreover, inverted T waves after revascularisation have been illustrated as reliable ECG markers for IS estimation. Accordingly, evaluation of various scoring systems for IS estimation have been of great interest in the past decades. Especially the modified Selvester QRS score, a 37-criteria/29-points ECG scoring...
### Table 2  Univariable and multivariable linear regression analysis for the prediction of IS and MVO

|          | Univariable | Multivariable |
|----------|-------------|---------------|
|          | β           | P value       | β       | P value       |
| **IS**   |             |               |         |               |
| DETERMINE score | 0.492 | <0.001 | 0.223 | <0.001 |
| Selvester score | 0.386 | <0.001 | – | – |
| Hs-cTnT, ng/L | 0.651 | <0.001 | 0.468 | <0.001 |
| Peak hs-CRP, mg/L | 0.286 | <0.001 | – | – |
| Peak NT-proBNP, ng/L | 0.330 | <0.001 | – | – |
| TIMI flow pre-pPCI | –0.410 | <0.001 | –0.198 | <0.001 |
| TIMI flow post-pPCI | –0.116 | 0.017 | – | – |
| Anterior infarct localisation | 0.219 | <0.001 | – | – |
| **MVO**  |             |               |         |               |
| DETERMINE score | 0.352 | <0.001 | 0.139 | 0.008 |
| Selvester score | 0.257 | <0.001 | – | – |
| Hs-cTnT, ng/L | 0.565 | <0.001 | 0.506 | <0.001 |
| Peak hs-CRP, mg/L | 0.323 | <0.001 | – | – |
| Peak NT-proBNP, ng/L | 0.271 | <0.001 | – | – |
| TIMI flow pre-pPCI | –0.214 | <0.001 | – | – |
| TIMI flow post-pPCI | –0.104 | 0.033 | – | – |
| Anterior infarct localisation | 0.174 | <0.001 | – | – |

hs-CRP, high-sensitivity C reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IS, infarct size; MVO, microvascular obstruction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; pPCI, primary percutaneous coronary intervention.

### Table 3  Binary logistic regression analysis for the prediction of IS and MVO

|          | Univariable analysis | Multivariable analysis |
|----------|-----------------------|------------------------|
|          | OR (95% CI)           | P value                | OR (95% CI)           | P value                |
| **IS >19%** |           |                        |                       |                       |
| DETERMINE score | 1.30 (1.23 to 1.39)  | <0.001                 | 1.09 (1.02 to 1.17)  | 0.014                 |
| Selvester score | 1.26 (1.18 to 1.35)  | <0.001                 | –                      | –                     |
| Hs-cTnT, ng/L | 1.00 (1.00 to 1.00) | <0.001                 | 1.00 (1.00 to 1.00)  | <0.001                 |
| Peak hs-CRP, mg/L | 1.14 (1.08 to 1.20) | <0.001                 | –                      | –                     |
| Peak NT-proBNP, ng/L | 1.00 (1.00 to 1.00) | <0.001                 | –                      | –                     |
| TIMI flow 0 pre-pPCI | 0.21 (0.13 to 0.34) | <0.001                 | 0.40 (0.22 to 0.74)  | 0.003                 |
| TIMI flow 3 post-pPCI | 0.35 (0.19 to 0.66) | 0.001               | –                      | –                     |
| Anterior infarct localisation | 2.04 (1.37 to 3.04) | <0.001                 | –                      | –                     |

**MVO >1.4%**

|          | Univariable analysis | Multivariable analysis |
|----------|-----------------------|------------------------|
|          | OR (95% CI)           | P value                | OR (95% CI)           | P value                |
| DETERMINE score | 1.22 (1.16 to 1.29)  | <0.001                 | 1.12 (1.04 to 1.21)  | 0.003                 |
| Selvester score | 1.21 (1.14 to 1.29)  | <0.001                 | –                      | –                     |
| Hs-cTnT, ng/L | 1.00 (1.00 to 1.00) | <0.001                 | 1.00 (1.00 to 1.00)  | <0.001                 |
| Peak hs-CRP, mg/L | 1.17 (1.11 to 1.24) | <0.001                 | 1.13 (1.07 to 1.20)  | <0.001                 |
| Peak NT-proBNP, ng/L | 1.00 (1.00 to 1.00) | <0.001                 | –                      | –                     |
| TIMI flow 0 pre-pPCI | 0.29 (0.18 to 0.48) | <0.001                 | 0.52 (0.28 to 0.95)  | 0.033                 |
| TIMI flow 3 post-pPCI | 0.40 (0.22 to 0.75) | 0.004               | –                      | –                     |
| Anterior infarct localisation | 1.89 (1.24 to 2.88) | 0.003           | –                      | –                     |

hs-CRP, high-sensitivity C reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; IS, infarct size; MVO, microvascular obstruction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; pPCI, primary percutaneous coronary intervention.
system, has been suggested for IS assessment. However, it has recently been shown that the Selvester QRS score only has moderate association to CMR-determined IS. Moreover, due to the numerous criteria that have to be fulfilled for the Selvester score, this score is hardly applicable in clinical practice. Therefore, Lee et al introduced a simple ECG score based on the presence of abnormal ECG markers (combination of Q waves, fragmented QRS and inverted T waves) to estimate myocardial scar. They demonstrated in a cohort of 551 patients with ischaemic cardiomyopathy that the DETERMINE score estimated IS nearly as good as LVEF measured by CMR. However, due to the very large time gap between infarction and the ECG (median 5 years), the DETERMINE score might differ significantly if analysed in the acute setting after infarction because of the dynamic changes of the individual ECG markers especially in the early phase post-STEMI. Furthermore, CMR imaging was performed within 40 days after infarction, which is also a very large time gap between infarction and imaging since the most common time point for infarct severity assessment by CMR imaging is performed between days 3 and 5. Moreover, patients were excluded if the infarct mass was <10% in CMR imaging. The present analysis describes for the first time a close correlation of the DETERMINE score with IS and MVO determined by CMR in a large cohort of patients with STEMI. Above all, the DETERMINE score is a reliable tool for the exact estimation of myocardial damage after STEMI.

ECG markers and MVO
MVO, a severe marker of reperfusion injury, is common after STEMI treated with primary PCI with a prevalence of up to 50%. Presence of MVO is associated with worse LV function, larger IS and subsequently with higher risk of recurrent cardiovascular events. Identification of MVO is, therefore, of high relevance to allow an optimal risk stratification in the early stage after STEMI. CMR imaging currently offers the best tool in quantifying the presence and extent of MVO. However limited due to high costs and availability. The relation of ECG parameters with MVO assessed by CMR are scarce in the current literature either due to small study cohorts or using other reference methods for MVO quantification rather than CMR. Recently, we showed that patients with pathological Q waves on admission show more extensive MVO. Rommel et al demonstrated that QRS distortion on the admission ECG is significantly associated with MVO. In addition, patients displaying T-wave inversions significantly showed higher rates of MVO. In line with those prior findings, the DETERMINE score, a combination of the latter mentioned ECG markers, revealed a significant association with the presence as well as the extent of MVO. Accordingly, our results underline the value of the DETERMINE score for IS estimation and also for estimating microvascular injury in STEMI survivors.

Clinical implications
The DETERMINE score provides an almost simple and immediately available ECG score, combining established patterns of Q waves, fragmented QRS and inverted T waves, for IS estimation and assessment of MVO. In multivariable analysis, the DETERMINE score revealed a significant and independent association with both large IS and presence as well as extent of MVO even after adjustment for other established clinical parameters. However, further research is needed to evaluate the clinical applicability of the DETERMINE score in patients with STEMI.

Limitations
Our study has to declare some limitations. First, due to the inclusion of stable patients with STEMI with Killip class <3, these findings may not be applicable to unstable patients. Of note, the vast majority of patients with STEMI represent with Killip class <3. Second, CMR imaging was performed at a median of 3 days which might overestimate acute IS; however, in a recent scientific expert panel, CMR imaging is recommended 5±2 days after reperfusion. Third, the DETERMINE score should be validated in an independent STEMI cohort to prove the results from the present data for clinical applicability. Fourth, the DETERMINE score was analysed at discharge, thus, the predictive value may differ if measured at other time points. Although persistent ST elevation represents a marker of IS and MVO, it was not included in the DETERMINE score. Further studies are necessary to evaluate the comparative value of persistent ST elevation and the DETERMINE score. Finally, pathological Q waves were used as a dichotomous variable as required for the DETERMINE score, although recent data suggest that continuous variable of Q waves might show better association with IS as well as MVO. Furthermore, we cannot fully exclude other confounders resulting in pathological Q waves; however, according to our exclusion criteria, patients with known history of cardiac diseases were excluded.

CONCLUSION
A simple ECG score, representing a combination of Q waves, fragmented QRS and T-wave inversions, ascertained from the discharge ECG, is independently associated with the extent of myocardial injury after STEMI. Thus, the DETERMINE score may represent as a reliable, and rapidly available tool for estimating the extent of myocardial as well as microvascular injury.
